Current report No. 7/2024 – Opinion of the Supervisory’s Board on the Management Board’s recommendation on the payment of the dividend

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. 
Date: 24/05/2024, g.17:13

In relation to the current report no. 5/2024 of 23 May 2024 on Management Board's recommendation on the payment of the dividend, the Management Board of Celon Pharma S.A. (“Company”) hereby informs that on 24 May 2024 the Supervisory Board of the Company has given a positive opinion on the recommendation of the Management Board of Celon Pharma S.A. for the Ordinary General Meeting of the Company on the payment of the dividend referred to in the aforementioned report no. 5/2024.

The final decision on coverage of the loss for the financial year 2023 and on payment of the dividend will be made by the Ordinary General Meeting of the Company.